SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 target decision on deramiocel for Duchenne muscular dystrophy, with traders weighing whether the amended application and longer-term upper-limb data could support approval. Bullish speculation has been reinforced by commercial-launch job postings and optimism about FDA flexibility, while skeptics cite prior advisory-panel concerns and caution that hiring does not guarantee approval; INOs separate FDA approval has also provided a sentiment tailwind.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a broad crypto pullback, with traders debating whether concerns over Binances reported security incident and exchange trust are adding pressure or coinciding with an existing market downtrend. Sentiment is split between bearish calls for further weakness and buyers treating the decline as an opportunity to accumulate and stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.19280151 USD and is up 0.00 over the last 24 hours. It is currently trading on 1752 active market(s) with $154,401,668.14 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs volatile price action and technical levels dominate the discussion, with traders debating whether rebounds and breakout setups can hold or whether further weakness will follow. Sentiment is sharply divided between dip-buying and short-squeeze hopes on one side, and concerns about continued losses and a lack of altcoin momentum on the other.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries, including sharply higher overseas sales, are driving discussion, but traders are debating whether volume growth can translate into better margins and meet the companys Q4 delivery ambitions. The upbeat operating update is being weighed against a steep share-price decline and concerns about China EV competition and profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A modest rebound has prompted pump and short-squeeze chatter around the Trump-themed meme coin, while most discussion focuses on its steep decline and accusations that it is a speculative pump-and-dump. Some holders remain bullish, but skeptics warn of further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical peers, with traders pointing to broader risk-off sentiment and concerns about dilution, valuation, and execution rather than a clear company-specific setback. Bulls are buying the dip on data-center optics demand and upcoming earnings, while skeptics remain wary of further declines.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high ahead of the Q3 report is driving attention, with bullish traders pointing to BRIUMVIs commercial growth and speculating about a short squeeze or buyout. Others caution that the buyout talk is unconfirmed and that the earnings results and upcoming subcutaneous BRIUMVI data will be important tests of the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Positioning around Luckins scheduled third-quarter earnings report is the main focus, with traders hoping for strong results and a rally while others expect a post-report pullback. The debate is amplified by frustration over the stocks prolonged weak, range-bound trading and speculation about buybacks or a future relisting.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat and strong refining results are driving attention, with traders highlighting higher shareholder returns and record-high shares. The reaction is broadly positive, though some caution that the stock looks extended and refining strength may not last if margins normalize.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads strong third-quarter results and raised outlook, led by continued HIV drug demand, are driving attention as shares reach fresh highs. Traders are broadly upbeat about the earnings and breakout, though some remain cautious after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates

Icon PLC (ICLR) delivered earnings and revenue surprises of +0.76% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ICON Reports Third Quarter 2026 Results

ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the third quarter ended September 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027115066/en/ Chief Executive...

Analysts Estimate Alignment Healthcare (ALHC) to Report a Decline in Earnings: What to Look Out for

Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's How Much $1000 Invested In Icon 20 Years Ago Would Be Worth Today

Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 2.59% on an annualized basis producing an average annual return of 11.6%. Currently, Icon has a market capitalization of $12.68 billion.
Buyingread more...

ICON Schedules Third Quarter 2026 Earnings Conference Call

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the third quarter 2026 after the market closes on Tuesday, October 27, 2026. The company will hold a conference call and webcast to discuss its financial results...

CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability

ICON plc (NASDAQ: ICLR) (ICON), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its environmental, social and governance (ESG) priorities with cutting-edge clinical innovation to drive both industry-leading...

Insider Selling: Linda Grais Unloads $138K Of Icon Stock

Linda Grais, Director at Icon (NASDAQ:ICLR), executed a substantial insider sell on August 12, according to an SEC filing.
What Happened: Grais opted to sell 841 shares of Icon, according to a Form 4 filing with theread more...

• Reported GAAP EPS of $2.66 down -16.88% YoY
• Reported revenue of $2.02B down -2.86% YoY
• ICON updated 2026 full-year guidance, with revenue expected in the range of $8.1B and adjusted diluted earnings per share expected in the range of $10.35-$10.65.

ICON reported lower Q3 revenue and adjusted EBITDA, adjusted diluted EPS below Q3 2025, and disclosed exposure to pharmaceutical-industry and client dependence, competition, consolidation, and service-demand conditions.

ICON reported gross bookings and net business wins alongside a $24.5B backlog; its AI-enabled platform resonates with customers, and it generated $302.4M free cash flow and repurchased $400M stock.

ICON plc engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The firm specializes in the development, management, and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S., and Rest of World. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Icon Plc

ICLR Stock Crashed 33% In Pre-Market Today - Why Did The Company Withdraw Its FY2025 Guidance?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The company had initially forecast FY2025 revenue between $8.05 billion and $8.10 billion.</li><li>Preliminary findings suggest that revenue for FY 2023 and 2024 may have been overstated by less than 2%, Icon said.</li><li>Icon plans to release its Q4 and FY2025 earnings results on or prior to April 30, 2026.</li></ul>Shares of Icon Plc (ICLR) fell more than 33% in premarket trading on Thursday after the company withdrew its full-year 2025 guidance and said revenue for 2023 and 2024 may have been overstated.If the premarket level holds after the opening bell, <a href="https://stocktwits.com/symbol/ICLR">ICLR shares</a> would be trading at their lowest levels since May 2017.<h2 class="st-heading-2">Investigation Into Accounting Practices</h2>The company disclosed an ongoing internal investigation by its audit committee, launched in late October 2025, into certain accounting practices and controls, primarily centered on revenue recognition for fiscal years 2023 through 2025.As a result, Icon will not be able to report its 2025 financial results and has subsequently withdrawn its full-year guidance. Preliminary findings also suggest that revenue for FY 2023 and 2024 may have been overstated by less than 2%.<h2 class="st-heading-2">What Guidance Did Icon Withdraw?</h2>The company had earlier forecast FY2025 revenue between $8.05 billion and $8.10 billion and adjusted diluted earnings of $13–$13.20 per share. It also reported revenue of $8.28 billion in FY2024 and $8.12 billion in FY2023.Icon said it intends to release its fourth-quarter (Q4) and FY2025 earnings results on or prior to April 30, 2026.“In response to the current investigation, we are implementing a series of corrective actions to enhance our internal controls over financial reporting,” CEO Barry Balfe said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp selloff in pre-market, retail sentiment on Stocktwits flipped to ‘ extremely bullish’ from ‘bearish’ a day earlier, amid ‘ extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ICLR_jpg_6e87361557.webp" alt="ICLR.jpg" width="918" height="90"><figcaption>ICLR's Sentiment Meter and Message Volumes at Premarket on Feb. 12, 2026 | Source: Stocktwits</figcaption></figure>One user considered whether to invest in the shares for a “quick turnaround.”<stembedurl>https://stocktwits.com/Wallstfan/message/644772393</stembedurl>Year-to-date, the stock has declined by almost 50%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/soybeans-rally-trump-xi-call-us-china-trade-truce/cZRTlXHR4rO">Trump and Xi’s Two-Hour Call Triggered A Rally In This Commodity - It's Not Gold Or Silver</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial charts on a computer screen while engaging in a discussion about market trends with a client over the phone, demonstrating expertise in investment strategies. 

The company disclosed an ongoing internal investigation into certain accounting practices and controls, primarily on revenue recognition for fiscal years 2023 through 2025.

Why Is ICLR Stock Down Today? Icon Flags Accounting Issues, Withdraws FY25 Guidance

iShares MSCI Ireland ETF

Victory Portfolios II - VictoryShares Nasdaq Next 50 ETF

Alpha Architect Etf Trust - The Generation Z ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$211.36
Prev Close	$215.48
Open	$211.52
Dividend Yield	0.00%
50-Day Moving Average	$171.97
Beta	1.14
Avg. Volume	1.06M
PE Ratio	36.43

52-Week High	$219.04
52-Week Low	$66.57
Market Capitalization	$16.31B
EPS (Annual)	$2.90
Price to Book	1.73
Revenue Per Employee	$205,769.08

Feed

News

Sentiment

Earnings

Fundamentals

Info

ICLR Fundamentals